Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs
Breast Cancer, DCIS
About this trial
This is an interventional supportive care trial for Breast Cancer focused on measuring breast cancer, DCIS, aromatase inhibitor
Eligibility Criteria
Inclusion Criteria:
- ≥ 18 years old at the time of informed consent
Regular access to a smartphone capable of downloading the application
- iOS 11 or later (iPhone5, iPhone SE or newer)
- Android 6 or later (Android 9 is current version)
- History of DCIS, stage I, II, or III invasive breast cancer
Currently prescribed an aromatase inhibitor (letrozole, anastrozole, exemestane) or planned to be initiated on one by the time of signing informed consent. Patient already on an AI must have been prescribed this medication for a total of 36 months or less.
- Ovarian suppression with AI is allowed in premenopausal patients.
- Prior SERM and now switching to an AI for the first time is allowed.
- Concurrent trastuzumab, pertuzumab, or TDM1 is allowed.
- Concurrent neratinib or other oral cancer directed medication is not allowed.
- ECOG performance status of 0-2
Exclusion Criteria:
Metastatic breast cancer or other active malignancy
- Locally recurrent breast cancer is allowed if treated with surgical excision and AI is prescribed with curative intent.
- History of prior treated malignancies, other than breast cancer, that are now stable, are in remission, and do not require active therapy, are acceptable
- Unable to read the English language or otherwise participate in the study procedures in the opinion of the treating investigator.
Sites / Locations
- Indiana University Melvin & Bren Simon Cancer Center
Arms of the Study
Arm 1
Experimental
Mobile Health Application Intervention
LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating "to-do" lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added.